Suggested remit: To appraise the clinical and cost effectiveness of belimumab within its marketing authorisation for treating lupus nephritis.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
 
Status Suspended
Process STA 2018
ID number 2722

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 January 2022 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
23 August 2021 (10:00) Scoping workshop
06 July 2021 - 03 August 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual